Revvity (NYSE:RVTY) Issues Earnings Results

02 Feb 2026, 09:22 by Teresa Graham · The Cerbat Gem

Revvity (NYSE:RVTY – Get Free Report) posted its quarterly earnings results on Monday. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15, Briefing.com reports. Revvity had a return on equity of 7.52% and a net margin of 8.44%.During the same period in the prior year, the business earned $1.42 earnings per share. The firm’s revenue was up 5.9% compared to the same quarter last year. Revvity updated its FY 2026 guidance to 5.350-5.450 EPS.

Here are the key takeaways from Revvity’s conference call:

Revvity closed Q4 with stronger-than-expected results—Q4 organic growth of 4% and adjusted EPS of $1.70, while full-year adjusted EPS of $5.06 topped guidance; management repurchased over $800M of shares in 2025 (>$1.5B since 2023).
2026 initial guidance is conservative — management forecasted 2%–3% organic growth, total revenue of $2.96B–$2.99B, 28% adjusted operating margin, and adjusted EPS of $5.35–$5.45, but said upside is possible if end markets improve.
Diagnostics drove Q4 strength (diagnostics organic +7%), led by reproductive health and immunodiagnostics, while life-sciences reagents were flat and instruments showed a meaningful sequential recovery, signaling improving demand trends.
Strategic software push — Revvity launched the Signals Synthetica AI platform, closed the ACD/Labs acquisition (expected to add ≈$20M revenue / ~75bps), and announced a collaboration with Lilly to accelerate adoption of its Signals software.
Ongoing headwinds — DRG-related volume pressures in China are expected to persist through about the end of Q2, and Q1 adjusted operating margins are guided down to about 23% due to an extra operating week, tariffs, and cost programs not yet fully implemented.

Revvity Stock Performance

NYSE RVTY opened at $108.48 on Monday. Revvity has a 52-week low of $81.36 and a 52-week high of $128.04. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 1.75. The firm has a 50-day moving average of $103.96 and a 200-day moving average of $95.44. The stock has a market cap of $12.30 billion, a PE ratio of 54.51, a P/E/G ratio of 3.32 and a beta of 1.06.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Stockholders of record on Friday, April 17th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, April 17th. Revvity’s dividend payout ratio (DPR) is presently 14.07%.

Revvity announced that its board has authorized a share repurchase plan on Monday, October 27th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 8.7% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RVTY. UBS Group AG increased its holdings in Revvity by 22.3% in the 3rd quarter. UBS Group AG now owns 2,179,505 shares of the company’s stock valued at $191,034,000 after buying an additional 397,160 shares during the period. Invesco Ltd. increased its stake in Revvity by 15.7% in the third quarter. Invesco Ltd. now owns 2,553,515 shares of the company’s stock valued at $223,816,000 after acquiring an additional 346,313 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in Revvity in the second quarter valued at about $30,106,000. Bank of America Corp DE grew its holdings in shares of Revvity by 40.7% during the third quarter. Bank of America Corp DE now owns 752,567 shares of the company’s stock worth $65,963,000 after purchasing an additional 217,596 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Revvity by 430.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 256,317 shares of the company’s stock valued at $22,466,000 after purchasing an additional 208,028 shares during the period. Institutional investors own 86.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on RVTY shares. Weiss Ratings restated a “sell (d)” rating on shares of Revvity in a research note on Monday, December 29th. Wells Fargo & Company increased their target price on shares of Revvity from $102.00 to $107.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Bank of America cut Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price objective for the company. in a research report on Monday, December 15th. Robert W. Baird lifted their price objective on Revvity from $122.00 to $123.00 and gave the stock an “outperform” rating in a report on Tuesday, October 28th. Finally, Evercore ISI reiterated an “outperform” rating on shares of Revvity in a research note on Monday, January 5th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Revvity currently has a consensus rating of “Hold” and an average target price of $113.91.

Read Our Latest Report on Revvity

Revvity Company Profile

(Get Free Report)

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.